Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 35: 1752-1756, 1989;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wu, A. H.
Right arrow Articles by Chen, H. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wu, A. H.
Right arrow Articles by Chen, H. L.

Clinical Chemistry, Vol 35, 1752-1756, Copyright © 1989 by American Association for Clinical Chemistry

Role of rapid immunoassays for urgent ("stat") determinations of creatine kinase isoenyme MB

AH Wu, TG Gornet, CC Harker and HL Chen
Department of Pathology, University of Texas Medical School, Houston 77030.

We compared the analytical performance of three immunoassays used to rapidly determine creatine kinase (EC 2.7.3.2; CK) isoenzyme MB in serum: Dade's "Stratus," Corning's "Magic Lite," and Hybritech's "Icon QSR CK-MB." Performance criteria included precision, analytical sensitivity, sample stability, and analytical and clinical correlation of results for serum samples taken from healthy individuals, patients with suspected and confirmed acute myocardial infarction, and patients after coronary artery bypass surgery. We also examined 31 samples taken from patients in the emergency room suspected of myocardial infarction, to evaluate the potential of these assays for early diagnosis. Although these assays differ in the manner in which CK-MB is measured, and therefore have different procedural requirements, we conclude that they are equivalent in overall assay performance. None of these assays, however, is sufficiently sensitive for early diagnosis of myocardial infarction; therefore, results cannot be used by cardiologists in deciding whether acute thrombolytic therapy should be given. Other management decisions, such as the optimal utilization of intensive-care bed space, may justify using these assays on a "stat" basis.


The following articles in journals at HighWire Press have cited this article:


Home page
 NEJMHome page
P. R. Puleo, D. Meyer, C. Wathen, C. B. Tawa, S. Wheeler, R. J. Hamburg, N. Ali, S. D. Obermueller, F. J. Triana, J. L. Zimmerman, et al.
Use of a Rapid Assay of Subforms of Creatine Kinase MB to Diagnose or Rule Out Acute Myocardial Infarction
N. Engl. J. Med., September 1, 1994; 331(9): 561 - 566.
[Abstract] [Full Text]

Home page
 NEJMHome page
C. W. Hamm
New Serum Markers for Acute Myocardial Infarction
N. Engl. J. Med., September 1, 1994; 331(9): 607 - 608.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1989 by the American Association for Clinical Chemistry.